Search clinical trials for: BI 409306 BS

Total 1321 results

Boehringer Ingelheim

Completed

A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Dermatitis, Atopic

United States, Japan, Canada
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Australia, Canada, Germany, Spain, Taiwan, Hungary, Poland, Korea, Republic of, Austria, New Zealand, United Kingdom, Czechia, Puerto Rico
Cartiheal (2009) Ltd

Completed

Evaluation of the Agili-C Biphasic Implant in the Knee Joint

Cartilage Diseases | Osteochondritis Dissecans

Czechia, Italy, Croatia, Hungary, Poland, Romania, Serbia, Slovenia
University of California, San Diego

Completed

Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA

Chronic Obstructive Pulmonary Disease | Obstructive Sleep Apnea | Overlap Syndrome

United States
Ryerson University

Completed

HIV Prevention for HIV-Negative Men Via Reduction of Social Anxiety

Substance Use | Social Anxiety

Canada
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Healthy
European Organisation for Research and Treatment...

Completed

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Endometrial Cancer | Melanoma (Skin)

Belgium
Chang Gung Memorial Hospital

Withdrawn

Efficacy of Unilateral Versus Bilateral Approach to Robot-Assisted Rehabilitation in Patients With Subacute Stroke

Subacute Stroke

Taiwan
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial

Asthma in Children

United States
Response Pharmaceuticals

Completed

Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

Hypertriglyceridemia

Germany
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Healthy | Renal Impairment

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated

Healthy

Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers

Healthy Volunteers

Germany
Boehringer Ingelheim

Completed

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

Healthy

Japan, Korea, Republic of
Boehringer Ingelheim

Terminated

Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms

Healthy

Netherlands
Manchester Metropolitan University
Manchester University NHS Foundation Trust

Unknown

Non Invasive Ventilation for Acute Exacerbations in Adult CF (NIVinCF)

Respiratory Failure | Cystic Fibrosis

United Kingdom
Boehringer Ingelheim

Completed

First in Man Trial of BI 113608

Healthy

Germany
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Healthy

United States
US Department of Veterans Affairs

Completed

Veterans Intensive Personalized Treatment in Heart Failure (VIP)

Heart Failure

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Withdrawn

Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.

HIV Infections | Healthy
Chroma Therapeutics

Terminated

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Universiteit Antwerpen

Completed

Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area (OAETanzania)

Epilepsy | Onchocerciasis

Tanzania
University of Colorado, Denver
National Cancer Institute (NCI)

Completed

Improving Physical Activity Maintenance of Cancer Survivors

Cancer

United States
AbbVie
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Asthma

United States, Korea, Republic of, Belgium, Taiwan, Canada, Germany, United Kingdom, France, Netherlands, Poland
Patri-cia Angelica de Miranda Silva Nogueira

Completed

CPAP Versus Bi-level in Chronic Heart Failure (CHF)

Heart Failure
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution

Healthy

Germany
St. Jude Children's Research Hospital

Completed

Constraint-Induced Movement Therapy in a Pediatric Oncology Population (SJCIT)

Brain Tumor | Hemiplegia

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Schizophrenia

Korea, Republic of, Canada, United States, Taiwan, United Kingdom, Chile, Serbia, Brazil, China, Colombia, Germany, Greece, Italy, Japan, Mexico, Norway, Poland, Sweden, Spain, Argentina, Croatia, France, Slovakia, Denmark, Malaysia, Czechia and more
Boehringer Ingelheim

Active, not recruiting

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Schizophrenia

United States, United Kingdom, Taiwan, Germany, Bulgaria, Mexico, Argentina, Denmark, Korea, Republic of, Austria, China, Belgium, Czechia, Finland, Serbia, Brazil, Portugal, Lithuania
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects

Healthy
Northwestern University
National Cancer Institute (NCI); National Comprehensive Cancer Network

Withdrawn

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia

United States
Inreda Diabetic B.V.
Stichting Robopump; Rijnstate ziekenhuis; Kinder Diabetes Centrum Nijmegen

Completed

Portable Artificial Pancreas Applied for Youth and Adolescents (PAPAYA 1)

Diabetes Mellitus, Type 1

Netherlands
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Turku University Hospital
University of Turku

Completed

Novel Imaging in Staging of Primary Prostate Cancer (PROSTAGE)

High Risk Prostate Cancer

Finland
Boehringer Ingelheim

Completed

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

United States, Singapore, Korea, Republic of, Germany, Japan, Malaysia, China, France, Thailand, Tunisia, Switzerland, Taiwan
Boehringer Ingelheim

Completed

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Healthy
Rami Khayat

Completed

Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure

Heart Failure | Sleep Apnea
Ligue Pulmonaire Genevoise

Completed

Patient-ventilator Interactions in Long Term Non-invasive Ventilation: Influence of Back-up Frequency

Obesity | Non Invasive Ventilation

Switzerland
Boehringer Ingelheim

Completed

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects

Healthy
Cairo University

Completed

Maxillary Versus Bi-Maxillary Posterior Segments Intrusion Adult Subjects With Skeletal Open Bite

Dental Malocclusion

Egypt
Boehringer Ingelheim

Completed

A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy

Colitis, Ulcerative

United Kingdom, Denmark, Germany, Spain, Netherlands, Norway

3

Subscribe